Launching its third seasonal prevention initiative under the slogan “Une infection respiratoire, c’est tout sauf tendance,” the Ministry of Health and Social Security has deployed a comprehensive public health campaign targeting influenza, COVID-19, respiratory syncytial virus (RSV), pertussis, and pneumococcal pneumonia as winter pathogen circulation begins.
In Plain English: The Clinical Takeaway
- Intranasal Vaccination Option: Children aged 2 to 17 can now receive the influenza vaccine via a needle-free nasal spray directly from their general practitioner or pediatrician at no cost.
- Broadened RSV Protection: A targeted immunization against RSV is accessible for adults aged 75 and older, as well as individuals aged 65 and over with specific underlying health conditions.
- Layered Mitigation: Standard hygiene protocols—including handwashing, daily room ventilation, and mask-wearing during symptomatic phases—remain essential alongside immunization.
Expanding Pediatric Influenza Prevention With Intranasal Delivery Systems
As seasonal respiratory pathogens enter the community, the public health initiative places a primary focus on expanding immunization coverage to reduce severe disease burdens and healthcare system strain. The ministry reported that the 2026 campaign introduces a major clinical update: children between the ages of 2 and 17 years inclusive can receive the influenza vaccine as an intranasal spray without cost during a standard consultation with a general practitioner or pediatrician.
Childhood influenza infections frequently require young patients to stay home from school, day-care facilities, and family activities for multiple days. Clinical studies, such as research published via PubMed (PMID: 30658873), indicate that needle-free administration improves acceptance rates among both pediatric patients and their parents compared to traditional intramuscular injections. Beyond individual protection, this mucosal delivery method helps limit viral transmission within households and shields vulnerable family members.
Standard injectable influenza vaccines remain available for children and parents who prefer them, individuals with medical contraindications to the nasal spray, or in the event of intranasal stock depletion. These injectable formulations are provided free of charge at pharmacies upon presentation of a medical prescription, matching the protocol established during the winter season 2025-2026.
Targeting High-Risk Populations and Healthcare Workers
Healthcare professionals and clinical personnel engaging in regular patient contact serve as vital actors in disease mitigation. The ministry emphasizes that vaccination among medical staff acts simultaneously as an individual shield and a professional duty toward vulnerable individuals under their daily care. Uncontrolled influenza outbreaks in clinical settings risk triggering severe complications, hospitalizations, or fatal outcomes among vulnerable patients.
To evaluate and manage regional viral circulation, the Directorate of Health resumed its weekly surveillance reporting in October. These comprehensive epidemiological reports track the trajectory of seasonal respiratory infections week by week and remain accessible for public review via santesecu.lu.
Parallel to influenza mitigation, the campaign addresses the severe clinical risks posed by respiratory syncytial virus (RSV). Infections can exacerbate pre-existing cardiac or pulmonary pathologies, culminating in acute respiratory distress, hospitalization, or mortality.
To counter this risk, an RSV vaccine is available for older adults. It is covered for people aged 75 and older—particularly those living in institutions—as well as people aged 65 and older with a comorbidity increasing the risk of a severe form of RSV infection. Patients are advised to consult their treating physicians to determine eligibility.
| Target Population | Pathogen Focus | Intervention Strategy | Delivery Mechanism |
|---|---|---|---|
| Children (Ages 2–17) | Influenza | Seasonal Immunization | Intranasal Spray (Free via GP/Pediatrician) |
| Seniors (Ages 75+ / 65+ with Comorbidities) | Respiratory Syncytial Virus (RSV) | Targeted Prevention | Vaccine (Consultation required) |
| Healthcare Professionals | Influenza & Respiratory Viruses | Occupational Shielding | Standard Immunization Protocols |
Contraindications & When to Consult a Doctor
Intranasal influenza vaccines carry specific age parameters (limited to ages 2 through 17).
Individuals experiencing symptoms should avoid close contact with vulnerable people. Vulnerable populations—including the elderly and those managing chronic cardiac, pulmonary, or immune disorders—should contact their healthcare provider to prevent rapid clinical deterioration.
Sustaining Non-Pharmacological Interventions
Immunization operates alongside essential non-pharmacological hygiene protocols to reduce community transmission. Public health guidance directs individuals to maintain frequent hand hygiene using soap and water, ensure daily room ventilation regardless of outdoor temperatures, and avoid close interactions with vulnerable populations when experiencing symptoms.
Additional measures include wearing a protective mask when coughing, running a fever, or entering healthcare environments, alongside practicing proper respiratory etiquette by coughing or sneezing into the inner elbow rather than the hands. Through this dual approach of broad vaccination coverage and consistent barrier gestures, public health authorities aim to suppress viral transmission and preserve healthcare system capacity through the winter months.
References
- Ministère de la Santé et de la Sécurité sociale. Official press release and campaign details.
- Direction de la Santé. Weekly epidemiological surveillance reports on winter respiratory infections. Available via santesecu.lu.
- PubMed Central. Acceptability and clinical evaluation data regarding intranasal influenza immunization. PMID: 30658873.
